PT-141 vs Viagra (and Cialis): brain versus blood flow
Reviewed 12 sourcesPublished by PepVault
PT-141 vs Viagra and Cialis: how each works, what the label trials found, onset, side effects with rates, and which one the evidence favors for which problem.

- Last reviewed
- Sources
- 12
- Questions
- 8
- Compounds
- 1
The short answer
Viagra and Cialis widen blood flow into the penis and work only with arousal; PT-141 (bremelanotide, sold as Vyleesi) acts on brain receptors tied to desire. For erections, the pills win clearly: in Pfizer's trials, 74 to 82% of men on 50 or 100 mg Viagra reported better erections, against 24% on placebo. PT-141 is approved only for low desire in premenopausal women.
Evidence: Viagra and Cialis: 43 label trials in more than 7,000 men between them. PT-141: two phase 3 trials in premenopausal women; in men, small clinic studies and one 342-man trial under an expression of concern.

How does PT-141 work differently from Viagra?
An erection starts when arousal releases nitric oxide in the penis, which raises a messenger called cGMP, relaxes the smooth muscle and lets blood flow in. Sildenafil (Viagra) and tadalafil (Cialis) block PDE5, the enzyme that breaks cGMP down, so the signal lasts longer23. Both labels say it plainly: without sexual stimulation, they have no effect23.
Bremelanotide (PT-141) works upstream. It switches on melanocortin receptors, and the label names two as the ones that matter at its dose: MC4R, found on nerve cells across the brain, and MC1R on pigment cells; how it raises desire, the label says, is unknown1. In healthy men, PT-141 produced erections measured in the clinic with no erotic video playing45. That is the core difference: the pills amplify arousal that is already there, and PT-141 acts on the arousal signal itself.
| Question | Viagra (sildenafil) | Cialis (tadalafil) | PT-141 (Vyleesi) |
|---|---|---|---|
| Approved for | Erectile dysfunction2 | Erectile dysfunction, enlarged prostate symptoms3 | Low sexual desire (HSDD) in premenopausal women1 |
| Works on | Blood flow in the penis2 | Blood flow in the penis3 | Brain melanocortin receptors1 |
| Needs arousal to work | Yes2 | Yes3 | In healthy men, erections came with no erotic video45 |
| Form | Tablet2 | Tablet3 | Injection under the skin1 |

Which works better for erections?
Viagra and Cialis, by a wide margin of evidence. Viagra was tested in 21 placebo-controlled trials in more than 3,000 men and beat placebo in all 212. Cialis was tested in 22 trials in more than 4,000 men3. PT-141 has no phase 3 trial in men: of the 10 bremelanotide studies on ClinicalTrials.gov in November 2026, every sexual-function trial enrolled only women11.
| Drug | Trial | What it measured | Result |
|---|---|---|---|
| Viagra 50 or 100 mg | 4 trials, 1,797 men, 12 to 24 weeks2 | Improved erections, one global question | 74% (50 mg) and 82% (100 mg) vs 24% on placebo2 |
| Viagra 50 to 100 mg | Diaries, about 1,600 men2 | Share of attempts that succeeded | About 66% vs about 20% on placebo2 |
| Cialis 20 mg | 2 US trials, 402 men, 12 weeks3 | Erection score out of 30 (IIEF-EF) | +6.9 and +9.3 points vs −0.2 and +0.33 |
| Cialis 20 mg | Same trials3 | Erection lasted long enough for intercourse | Up 34 and 44 percentage points vs up 5 and 43 |
| PT-141 nasal spray | Men who responded to Viagra, clinic study4 | Erection hardness (RigiScan) | Better than placebo at doses above 7 mg4 |
The IIEF erection score is a questionnaire about the past 4 weeks, where higher is better3. The PT-141 studies measured something narrower: hardness and duration of an erection in the clinic, with a gauge called RigiScan, over hours rather than months45.
Can PT-141 help when Viagra doesn't work?
This is where PT-141 has its most interesting result. Rosen 2004 tested it in men whose erections were good enough for sex half the time or less on 100 mg Viagra; injected PT-141 at 4 or 6 mg beat placebo at both doses in the clinic5. The largest men's trial, 342 married men in Tehran for whom sildenafil had failed, used a 10 mg nasal spray at home for at least 16 attempts: 51 men on the spray (33.5%) had a positive result, against 13 (8.5%) on placebo7. Those shares fit about 152 men a group, not the 172 and 170 randomized, and the abstract does not say who was counted7.
In January 2023 The Journal of Urology put that trial under an expression of concern, a public flag that the editors have questions about it, one of 14 it placed on the first author's papers712. Its number is the least secure in this guide. A 2026 systematic review counted 12 studies with 372 men across every peptide for male sexual function. It found melanocortin agonists such as PT-141 gave the most consistent erection gains, including in sildenafil non-responders, and called the evidence limited by small samples and short follow-up8. The full table of men's studies is in our PT-141 guide for women and men.
Can you take PT-141 with Viagra?
One small trial did. Nineteen men who responded to Viagra or Levitra took 25 mg sildenafil with 7.5 mg nasal PT-141, both low doses, then sildenafil alone and placebo, in random order6. The pair produced a greater erection response in the clinic than sildenafil alone, with no new side effects and none more frequent or severe than on sildenafil alone6.
The Viagra label takes the other side: it says combinations with other erectile dysfunction treatments were not studied in its program, may lower blood pressure further, and are not recommended2. The Cialis label says its combinations with other ED treatments have not been studied3. So the combination has one 19-man clinic study behind it, and no label covers it.
Does Viagra work for women, and PT-141 for men?
Each drug's weak spot is the other's approval. Sildenafil was tested in 781 women with sexual arousal disorder, 577 with normal estrogen and 204 low in estrogen, and did no better than placebo on any measure9. A 12-week trial in 202 postmenopausal women found gains in genital sensation and satisfaction, larger in women without low desire; women who also had HSDD saw no significant benefit10.
Vyleesi is the reverse: approved for women, with a label stating it is not for men and not for enhancing sexual performance1. In two 24-week trials in premenopausal women, a desire score running from 1.2 to 6 rose 0.5 and 0.6 points on the drug against 0.2 on placebo1. For low desire in women, PT-141 has the approval and the trials; Viagra has neither.
How fast does each work, and how long does it last?
| Timing | Viagra | Cialis | PT-141 (Vyleesi) |
|---|---|---|---|
| Label timing | About 1 hour before; anywhere from 30 minutes to 4 hours2 | Before sexual activity; works up to 36 hours after a dose3 | At least 45 minutes before1 |
| Peak blood level | 30 to 120 minutes, median 602 | 30 minutes to 6 hours, median 2 hours3 | About 1 hour1 |
| Half-life | About 4 hours2 | 17.5 hours3 | About 2.7 hours1 |
| Label limit | Once a day2 | Once a day3 | Once in 24 hours, 8 doses a month1 |
Cialis wins on the time window: one dose covers up to 36 hours, and 52% of men on 20 mg had a successful erection within 30 minutes, against 35% on placebo3. Viagra's effect lasted up to 4 hours in one study, weaker than at 2 hours2. In men, the first PT-141 erection came about 30 minutes after a nasal dose4; the Vyleesi label says how long each dose works is unknown1.
What are the side effects of each?
| Side effect | Viagra, as needed2 | Cialis 20 mg3 | Vyleesi, women1 |
|---|---|---|---|
| Headache | 16% vs 4% | 15% vs 5% | 11.3% vs 1.9% |
| Flushing | 10% vs 1% | 3% vs 1% | 20.3% vs 0.3% |
| Indigestion | 7% vs 2% | 10% vs 1% | Not listed |
| Nausea | Not listed at the as-needed dose | Not listed | 40.0% vs 1.3% |
| Stopped over side effects | 2.5% vs 2.3% | 3.1% vs 1.4% (10 or 20 mg) | 18% vs 2% |
Each figure is drug against placebo in that drug's own trials. The pills are the easier ones to live with: stopping over side effects barely differed from placebo23. Viagra also gives 3% of men on the as-needed dose a color tinge to vision, light sensitivity or blur, against none on placebo, mild and short-lived2. Vyleesi's nausea comes within about an hour, is worst with the first dose and improves for most people by the second; 8% stopped because of it1.
Commonly reported: men who try PT-141 describe more interest and arousal rather than only firmness, a warm flushed face, and queasiness after the first dose that is milder after that; Viagra users most often mention a headache and a stuffy nose.
Blood pressure moves in opposite directions. Sildenafil lowers it, by a mean 8.4/5.5 mmHg lying down in healthy volunteers2; tadalafil's drop did not differ from placebo3. Bremelanotide raises it, by up to 6/3 mmHg at 2 to 4 hours, slows the heart by up to 5 beats a minute, and is usually back to baseline within 12 hours1.
- Viagra and Cialis: never with nitrates such as nitroglycerin, or with riociguat, because blood pressure can fall sharply23.
- Vyleesi: not with uncontrolled high blood pressure or known heart disease1. It can slow the stomach, which can delay pills taken alongside it, and it lowers blood levels of oral naltrexone1.
- Vyleesi: darker patches of skin or gums in 1% at up to 8 doses a month, and in 38% after 8 daily doses1.
When to get help An erection lasting longer than 4 hours, or a sudden loss of vision in one or both eyes, is a reason to get medical care right away23.
Which one fits which problem?
- Erections that don't hold: Viagra or Cialis, tested in thousands of men, with stopping over side effects close to placebo23.
- A long window instead of timing a pill: Cialis, which works up to 36 hours after a dose3.
- Low desire in a premenopausal woman: Vyleesi, the one of the three with an approval and trials for it; sildenafil did not help women with HSDD110.
- Pills that no longer work: PT-141 has the most interesting signal, from small studies, one under an expression of concern578.
All three are prescription drugs, and starting one is a doctor's decision: the heart, blood pressure and nitrate checks above are part of the prescription123.
PepVault logs each dose with its time and any side effect you note, so the pattern after a first dose, such as nausea, flushing or a headache, is on record when you talk to your doctor. Log it in PepVault
Sources
- Vyleesi (bremelanotide injection) prescribing information. Cosette Pharmaceuticals. Revised October 2026; DailyMed version 2, November 9, 2026. dailymed.nlm.nih.gov
- Viagra (sildenafil citrate) prescribing information. Pfizer. Revised August 2017; DailyMed version 32, February 13, 2026. dailymed.nlm.nih.gov
- Cialis (tadalafil) prescribing information. Eli Lilly. DailyMed version 52, June 10, 2026. dailymed.nlm.nih.gov
- Diamond LE et al. Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PubMed 14963471
- Rosen RC et al. Subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PubMed 14999221
- Diamond LE et al. Co-administration of low doses of intranasal PT-141 and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005. PubMed 15833522
- Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008 (expression of concern, 2023). PubMed 18206919
- Ramez M et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med. 2026. PubMed 43002584
- Basson R et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med. 2002. PubMed 12150499
- Berman JR et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol. 2003. PubMed 14634409
- ClinicalTrials.gov: studies with bremelanotide as the intervention (searched November 20, 2026). clinicaltrials.gov
- Expression of concern: Salvage of sildenafil failures with bremelanotide. J Urol. January 10, 2023. PubMed lists 14 such notices in J Urol for the first author. PubMed 36626345
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.